Competition Heats Up For Beijing’s Vaccine Market
This article was originally published in PharmAsia News
Beijing, the first city to initiate free hepatitis A vaccination for children under China's nationwide immunity plan, has given the green light to GlaxoSmithKline and local enterprise Sinovac Biotech to provide inactivated hepatitis A vaccine. The two companies will effectively corner the Beijing free hepatitis A vaccine market for three years. According to public information, Sanofi Pasteur, GSK and Merck Sharpe & Dhome supply half of the paid vaccine market in the city. Officials at the China Association of Pharmaceutical Commerce believe foreign corporations will face fierce competitive bidding from domestic companies. Last year, Sanofi Pasteur was the only multinational company out of five pharmaceutical firms who won the tender for supplying Beijing with flu vaccine. (Click here for more - Chinese Language)
You may also be interested in...
Procter & Gamble, through its UK wellness subsidiary Nature's Best, is on-trend with new vegan vitamin D3 and iron supplements. Nature's Best has also launched three other vitamin D3 products in the country, as well as an ashwagandha supplement.
The MHRA has updated its guidance on regulatory flexibilities for medical devices and medicinal products resulting from COVID-19 to highlight how its approach differs from the EU.
The Swiss company is planning a US trial of CBSO, the first transcatheter septal occluder with a bioresorbable, metal-free frame.